Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 371, Issue 17, Pages 1577-1587Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1407426
Keywords
-
Categories
Funding
- Global Alliance for TB Drug Development
- Bill and Melinda Gates Foundation
- European and Developing Countries Clinical Trials Partnership
- U.S. Agency for International Development
- U.K. Department for International Development
- Directorate General for International Cooperation of the Netherlands
- Irish Aid
- Australia Department of Foreign Affairs and Trade
- National Institutes of Health, AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID) [UM1AI068634, UM1 AI068636, UM1AI106701]
- NIAID [1U01AI069469, 1U01AI069453, 1U01AI069426]
- MRC [MC_U122888469] Funding Source: UKRI
- Medical Research Council [MC_U122888469] Funding Source: researchfish
Ask authors/readers for more resources
BACKGROUND Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis. METHODS We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to test the noninferiority of two moxifloxacin-containing regimens as compared with a control regimen. One group of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18 weeks of isoniazid and rifampin (control group). In the second group, we replaced ethambutol with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (isoniazid group), and in the third group, we replaced isoniazid with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (ethambutol group). The primary end point was treatment failure or relapse within 18 months after randomization. RESULTS Of the 1931 patients who underwent randomization, in the per-protocol analysis, a favorable outcome was reported in fewer patients in the isoniazid group (85%) and the ethambutol group (80%) than in the control group (92%), for a difference favoring the control group of 6.1 percentage points (97.5% confidence interval [CI], 1.7 to 10.5) versus the isoniazid group and 11.4 percentage points (97.5% CI, 6.7 to 16.1) versus the ethambutol group. Results were consistent in the modified intention-to-treat analysis and all sensitivity analyses. The hazard ratios for the time to culture negativity in both solid and liquid mediums for the isoniazid and ethambutol groups, as compared with the control group, ranged from 1.17 to 1.25, indicating a shorter duration, with the lower bounds of the 95% confidence intervals exceeding 1.00 in all cases. There was no significant difference in the incidence of grade 3 or 4 adverse events, with events reported in 127 patients (19%) in the isoniazid group, 111 (17%) in the ethambutol group, and 123 (19%) in the control group. CONCLUSIONS The two moxifloxacin-containing regimens produced a more rapid initial decline in bacterial load, as compared with the control group. However, noninferiority for these regimens was not shown, which indicates that shortening treatment to 4 months was not effective in this setting. (Funded by the Global Alliance for TB Drug Development and others; REMoxTB ClinicalTrials.gov number, NCT00864383.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available